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SUMMARY
The epithelial-mesenchymal transition program becomes activated during malignant progression
and can enrich for cancer stem cells (CSCs). We report that inhibition of protein kinase C α
(PKCα) specifically targets CSCs, but has little effect on non-CSCs. The formation of CSCs from
non-stem cells involves a shift from EGFR to PDGFR signaling, and results in the PKCα-
dependent activation of FRA1. We identified an AP-1 molecular switch in which c-FOS and
FRA1 are preferentially utilized in non-CSCs and CSCs, respectively. PKCα and FRA1
expression is associated with the aggressive triple-negative breast cancers and the depletion of
FRA1 results in a mesenchymal-epithelial transition. Hence, identifying molecular features that
shift between cell states can be exploited to target signaling components critical to CSCs.
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INTRODUCTION
Cancer stem cells (CSCs), which are defined by their tumor-initiating properties, have been
identified within breast, colon, head and neck, lung and prostate carcinomas (Ailles and
Weissman, 2007). These cells appear to be responsible for driving tumor growth, recurrence
and metastasis (Al-Hajj et al., 2003; Dalerba et al., 2007). In experimental models of cancer
development, treatment of bulk cancer cell populations within tumors or cancer cell lines
propagated in culture with chemo- or radiotherapy has been shown to select for the
outgrowth of therapy-resistant subpopulations of cancer cells that are more tumorigenic,
invasive and stem-like (Creighton et al., 2009; Gupta et al., 2009). Hence, cancer therapies
may be rendered ineffective because the bulk of cancer cells within a tumor may be
eliminated while leaving behind CSC-enriched cells that proceed to regenerate tumors.
These tumors are often more malignant than was observed prior to treatment underscoring
the need for a detailed understanding of the molecular differences between CSCs and non-
CSCs to discover and exploit cell state-specific features that may render CSCs susceptible to
selective therapeutic intervention.
Numerous studies have used existing cancer cell lines to identify compounds that target cells
bearing specific gene mutations or exhibiting a more malignant phenotype; these studies did
not, however, address the specific effects of certain treatments on CSCs because the
representation of CSCs within these cell lines was poorly defined. In the case of breast
cancer, several markers, including CD44hi/CD24lo, aldehyde dehydrogenase (ALDH1+),
Hoechst dye efflux, and the retention of the PKH26 lipophilic dye, have been shown to
enrich for CSCs in various cell lines (Al-Hajj et al., 2003; Ginestier et al., 2007; Pece et al.,
2010). However, regardless of the enrichment procedure, these initially purified cells with
CSC properties often differentiate rapidly into cells exhibiting a non-CSC profile, making it
difficult to identify cell state-specific inhibitors in vitro.
CSCs are generated in some and perhaps all carcinomas as one of the products of an
epithelial-mesenchymal transition (EMT), indicating that these cells possess a more
mesenchymal phenotype that is associated with highly aggressive traits (Nieto, 2011; Thiery
et al., 2009). We undertook to develop a method by which we could clearly distinguish
chemical inhibitors that target breast CSCs from those that affect non-CSCs. Within normal
mammary epithelial cells (MECs), the forced expression of EMT-inducing transcription
factors (EMT-TFs) endows cells with mesenchymal traits accompanied by the loss of
epithelial markers. These cells were shown to possess enhanced stem cell activity in vitro
and in vivo (Mani et al., 2008; Morel et al., 2008). Likewise, in populations of weakly or
non-tumorigenic breast cancer cells, passage through the EMT program dramatically
increases CSC frequency along with the acquisition of mesenchymal properties that include
a distinctive CD44hi/CD24lo cell-surface marker profile, mammosphere-forming ability,
heightened resistance to chemotherapeutics, and increased tumor-initiating ability (Nieto,
2011; Thiery et al., 2009).
In the present work, we took a directed approach to discover key regulatory genes unique to
the mesenchymal state whose expression is elevated in CSCs.
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RESULTS
Identification of kinases expressed differentially in EMT-induced cells
To understand the molecular changes associated with epithelial cells that have passed
through an EMT, we transduced genes encoding the Twist, Snail and Slug EMT-TFs into
HMLE human MECs that had previously been immortalized through the introduction of the
hTERT and SV40 early-region genes (Mani et al., 2008). As anticipated, the resulting cells
(HMLE-Twist, HMLE-Snail and HMLE-Slug) displayed a set of mesenchymal markers and
were judged by these criteria to have undergone an EMT (Figures 1A and S1A). These cells
were predominantly CD44hi/CD24lo (data not shown) and formed mammospheres more
efficiently than the parental epithelial cells (Figure 1B), indicating they were enriched for
stem cell activity.
Using microarray gene expression analyses, we searched for kinase-encoding genes that
exhibited the greatest differences in expression in the EMT-TF-induced mesenchymal cells
relative to the parental HMLE cells. A group of kinase-encoding genes were overexpressed
at least two fold in HMLE-Twist, HMLE-Snail and HMLE-Slug cells relative to the HMLE
population (Figure 1C and Table S1). Several of these genes, including CLK1, EPHA2,
NME7, PRKCA (hereafter referred as PKCα), SGK1, SPHK1 and CDK6, have been reported
to promote cancer cell invasion and motility but were not previously implicated either as
components of the EMT transcription program or in the maintenance of mesenchymal and
CSC states. We validated the expression of the top selected kinase mRNAs by quantitative
PCR (Figure S1B).
The changes in the expression patterns of these kinases during the EMT suggested an
opportunity for selective therapeutic intervention using kinase inhibitors. We wished to
develop an assay that could be used to determine whether any of the upregulated kinases
could be pharmacologically targeted to preferentially kill the mesenchymal cells. Because
the mesenchymal cells analyzed above carried constitutively expressed EMT-TFs and were
therefore locked in the mesenchymal state, we reasoned their response to chemical inhibitors
might not be representative of mesenchymal cells that arise in vivo through the physiological
and presumably reversible upregulation of endogenous EMT-TFs, limiting the utility of the
EMT-TF vector-transduced cells in chemical inhibitor screens.
Therefore, we derived populations of HMLE cells that had spontaneously undergone an
EMT and stably resided thereafter in a mesenchymal state (Figure 1D). Hence, their
phenotypic state was governed by endogenously expressed EMT-TFs. We derived 11 such
lines, termed Naturally Arising MEsenchymal Cells (NAMECs), from bulk cultures of
HMLE cells. We found that NAMECs expressed elevated levels of endogenous EMT-TFs
(Twist, Snail, Slug and Zeb1) and associated markers (vimentin, N-cadherin and fibronectin)
as well as loss of the key epithelial adherens junction protein, E-cadherin (encoded by
CDH1) (Figures 1E, 1F, S1A and S1C). Similar to EMT-TF-induced cells and the resident
mammary epithelial stem cells that are naturally present within HMLE populations,
NAMECs were also predominately CD44hi/CD24lo (Figure 1G). They exhibited an 11.3-
fold higher mammosphere-forming ability relative to HMLE cells (Figure 1H). Thus,
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NAMECs exhibited characteristics of cells that have passed through an EMT and differed
greatly from parental HMLE cells.
Depletion of stem-like cells by select kinase inhibitors
To identify kinase inhibitors that selectively targeted mesenchymal-like cells bearing stem
cell properties, we established a screen that measured the ability of candidate inhibitors to
preferentially deplete mesenchymal NAMECs but not HMLE cells. We labeled one of the
NAMEC lines (NAMEC8) with the tdTomato red fluorescent protein (NAMEC-Tom) and
the HMLE cells with green fluorescent protein (HMLE-GFP). We then attempted to
reconstitute certain stem cell and non-stem cell interactions that might operate in vivo by
mixing the two cell populations in culture in a 5:1 ratio (Figures 2A and S2A). We then
challenged these cultures with a panel of kinase inhibitors. We initially targeted several
proteins kinases that were elevated in HMLE-Twist, HMLE-Snail, HMLE-Slug cells and
NAMECs relative to HMLE using of a panel of 15 commercially available kinase inhibitors
(Figures 1C, S1B and S2B). Figure 2B illustrates their effects on the proportion of surviving
NAMEC-Tom and HMLE-GFP cells at the end of a six-day treatment period and the
numbers of viable cells were quantified with flow cytometry to determine the fraction of
NAMEC-Tom or HMLE-GFP cells in inhibitor-treated populations relative to vehicle-
treated controls.
The four inhibitors targeting PKCα (PKC 20-28, Ro-31-8220, Ro-32-0432 and
bisindolylmaleimide I) showed a 6.8- to 12.1-fold lower LC50 (lethal concentration, 50%)
against NAMEC-Tom cells relative to HMLE-GFP cells (Figures 2C and 2D). These
findings were validated in three other NAMEC cell lines (Figures S2C and S2D). Since
PKCα was also elevated in CD44hi/CD24lo HMLE cells (Figure 2E), we tested whether
these stem-like cells were sensitive to the inhibitors. Indeed, treatment of bulk HMLE cells
with two different PKCα inhibitors reduced the CD44hi/CD24lo cell compartment whereas
the CD44lo/CD24hi population remained unaffected (Figure S2E).
While total and phosphorylated PKCα were overexpressed in a variety of derived
mesenchymal cells (Figure S2F), the phosphorylation status of PKCα is constitutive and not
a useful indicator of its activity (Newton, 2001). Furthermore, active site inhibitors, such as
bisindolylmaleimide, could paradoxically stabilize phosphorylated PKC (Cameron et al.,
2009; Gould et al., 2011). Accordingly, we validated PKC enzymatic activity in these cells
and found that the derived mesenchymal cells possessed on average 8.5-fold higher levels of
total PKC activity relative to HMLE cells (Figure 2F).
The inhibitors targeting PKCη, CLK1, CDK6 and JAK1 also appeared to deplete NAMEC-
Tom cells preferentially (Figure 2B). However, these agents were not included in
subsequent studies as only a single inhibitor was available against each of these kinases,
preventing us from controlling for possible off-target effects. In stark contrast to the effect of
the pathway-specific inhibitors, three non pathway-specific compounds, staurosporine,
doxorubicin and paclitaxel preferentially depleted HMLE-GFP cells instead (Figures 2B and
2D). This supported previous observations that non cell state-specific inhibitors can enhance
the representation of more aggressive cancer stem-like cells within heterogeneous cell
populations following treatment (Creighton et al., 2009; Gupta et al., 2009).
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To determine how PKCα inhibitors affected these more susceptible cell populations, we
tested whether they induced apoptosis. The mixed cell populations were treated with
Ro-31-8220 for three days and 89.4% of NAMEC-Tom cells underwent apoptosis in
comparison to 22.4% of the HMLE-GFP cells (Figure 2G). Conversely, paclitaxel and
staurosporine resulted in HMLE-GFP cell apoptosis, leaving NAMEC-Tom cells less
affected.
As it remained possible that the four PKCα inhibitors used in our analyses acted in an off-
target manner, we depleted PKCα with shRNA (Figure 2H). Mixed NAMEC-Tom and
HMLE-GFP cultures were infected with lentiviral shRNAs targeting PKCα and then seeded
separately, after sorting for either Tom+ or GFP+ expression. Consistent with the use of
chemical inhibitors, depletion of PKCα resulted in the substantial loss of NAMECs whereas
HMLE cells were less affected (Figure 2I). These observations confirmed the greater
dependence on PKCα-regulated signaling networks in cells that have passed through an
EMT program.
Conservation of cell state-specific features upon oncogenic transformation
To test whether neoplastic cells that have passed through an EMT program acquire a greater
potential to generate CSCs, we ectopically expressed comparable levels of H-RASG12V in
NAMECs and HMLE cells (Figure 3A). As few as 500 of the resulting NAMEC-RAS cells,
when implanted into NOD-SCID mice, were sufficient for tumor-initiation in six out of 10
hosts, whereas as many as 25,000 of the corresponding HMLE-RAS cells failed to form
tumors (Figure 3A). Based on a limiting dilution assay, the frequency of CSCs was
calculated to be approximately 1/2314 for NAMEC-RAS and 1/463783 for HMLE-RAS
cells. Thus, transformation of preneoplastic stem cells expressing mesenchymal traits gave
rise to CSCs far more efficiently than bulk epithelial cells.
To investigate whether PKCα inhibition would also preferentially affect CSC-enriched
NAMEC-RAS cells, we first determined if PKCα mRNA levels remained differentially
regulated between NAMEC-RAS and HMLE-RAS cell populations. We found that the
mRNA levels of PKCα and other kinase-encoding genes that were examined previously
remained higher in NAMEC-RAS cells compared to the HMLE-RAS cells; this echoed the
behavior of EMT-TF-induced mesenchymal cells that had been transduced with the
RASG12V vector (Figure 3B). We then mixed NAMEC-RAS cells labeled with tdTomato
(NAMEC-Tom-RAS) and HMLE-RAS cells labeled with GFP (HMLE-GFP-RAS) and re-
tested the effects of kinase inhibition and found that NAMEC-Tom-RAS cells were more
sensitive to PKCα inhibition relative to HMLE-GFP-RAS cells (Figure 3C). In contrast,
NAMEC-Tom-RAS cells were more resistant to paclitaxel and staurosporine than HMLE-
GFP-RAS cells (Figure 3C). When these various transformed cell populations were
implanted into NOD-SCID mice, NAMEC-RAS-derived tumors continued to express PKCα
but HMLE-RAS tumors did not (Figure 3D).
To assess the therapeutic utility of PKCα inhibitors, NAMEC-RAS cells were implanted in
NOD-SCID mice and treated for 30 days with a daily intraperitoneal dose of either a PKCα
inhibitor (Ro-31-8220) or a DMSO solvent control; additional control animals were left
untreated. These dosages were well-tolerated in mice and had no adverse effects after 30
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days of treatment followed by eight weeks of observation. Significant tumor burdens were
observed after 15 weeks in all control-treated mice whereas only four of eight mice treated
with PKCα inhibitor formed tumors (Figure 3E). Hence, PKCα inhibition reduced tumor-
initiating frequency and tumor growth of the CSC-enriched populations in vivo. We also
examined whether PKCα inhibition would have any effect on the growth of already-
established tumors. Xenografted NAMEC-RAS tumors were allowed to reach
approximately 2 mm in diameter (assessed by palpation) four weeks after implantation and
then exposed to treatments. Tumors from control-treated mice reached ~1.03 g six weeks
later, whereas those from PKCα inhibitor-treated mice only weighed ~0.25 g (Figure 3F).
These results demonstrated the therapeutic effects of PKCα inhibition on the continued
growth of already-established tumors.
A switch from EGFR to PDGFR signaling is induced upon EMT
The greater reliance of CSCs on PKCα led us to question whether cells that have passed
through an EMT respond to mitogenic and trophic signals differently from those that have
not. We attempted to trace the sources of the upstream signals that might be responsible for
activating PKCα and postulated that certain receptor tyrosine kinases induced by the EMT
program might be involved. We speculated that the EGF receptor (EGFR) might activate
PKCα in cells that had undergone an EMT, because EGFR overexpression and
amplification are positively associated with breast cancer progression (Carey et al., 2010).
However, in mesenchymal cell populations, the expression of endogenous total and
phosphorylated EGFRY1068 was reduced relative to HMLE cells (Figure 4A). Treatment of
co-mixed NAMEC-RAS-Tom and HMLE-RAS-GFP cells with either of two EGFR
inhibitors preferentially selected against HMLE-RAS-GFP cells (Figure 4B). Hence, the
more epithelial, non-CSC-enriched populations depended more strongly upon sustained
EGFR signaling than the mesenchymal CSC-enriched cell populations.
We used proteome analysis to identify potential RTKs associated with an EMT and
responsible for the activation of PKCα. The most differentially expressed RTK, exhibiting a
13-fold increase in representative peptides in HMLE-Twist cells relative to HMLE cells,
was PDGFRβ (encoded by PDGFRB) (data not shown). In addition, mRNAs of PDGFRA
(encoding PDGFRα) and PDGFRB, as well as their ligand PDGFC, were highly expressed
in basal B subtype of breast cancer cell lines bearing mesenchymal properties, but not in
luminal-like cell counterparts bearing more epithelial features (Figure 4C). PKCα mRNA
was also highly expressed in basal B, and not luminal-like, breast cancer cells (Figure 4C).
This is consistent with the notion that basal-like tumors contain cells that behave as if they
have undergone at least a partial EMT (Blick et al., 2008; Sarrio et al., 2008).
To determine whether PDGF autocrine signaling might be activated following an EMT, we
surveyed the expression of PDGFR ligands in the mesenchymal and epithelial cell
populations. PDGFA, PDGFB and PDGFD mRNAs were not expressed in either cell state
(data not shown), indicating that only PDGFC could participate in such autocrine signaling.
In mesenchymal cell populations, PDGFC mRNA was indeed upregulated (Figure 4D); total
and phosphorylated PDGFRα/β proteins were also induced in these cells (Figure 4E).
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Additionally, PDGFRA, PDGFRB and PDGFC mRNAs were upregulated specifically in the
CD44hi/CD24lo stem cell-enriched subpopulation (Figure S3A).
We also monitored the activity of PDGFR in the mesenchymal cell populations. Culturing
NAMECs for 24 hr in serum-free, growth factor-depleted medium reduced phosphorylation
of PDGFRβ modestly relative to NAMECs maintained in complete medium, whereas
application of either a PDGFR-neutralizing antibody or a PDGFR pharmacologic inhibitor
led to a 4.3- and 6.8-fold reduction, respectively, in p-PDGFRβY751 (Figure 4F).
Conversely, the exposure of the growth factor-depleted NAMECs to PDGFC resulted in
increased phosphorylation of PDGFRβ (Figure 4F), while HMLE cells showed no response
to PDGFC (data not shown). This provided further support for the specific activation of
autocrine PDGF signaling activity following induction EMT.
Levels of phospholipase C γ 1 and 2 (PLCγ1 and PLCγ2) proteins, which are known to
transduce signals from PDGFRα/β to PKCα (Rhee, 2001), were also elevated in the EMT
TF-transduced and NAMEC cells (Figure 4E). To examine whether PLCγ was activated by
PDGFR, NAMECs were treated with either of two PDGFR inhibitors (PDGFR Inh III and
PDGFR Inh IV). Levels of the two p-PLCγ1Y783 and p-PLCγ2Y1217 activated forms were
reduced, whereas total PLCγ1 and PLCγ2 protein levels remained unaltered (Figure S3B).
We next sought to determine whether PKCα activation was dependent on the observed
activations of PDGFR and PLCγ, the latter activates PKCα through its production of
diacylglycerol (Saito et al., 2002). Exposure of NAMECs to a PLCγ inhibitor (U73122)
reduced total PKC enzymatic activity (Figure S3C). Likewise, pharmacologic inhibition of
PDGFR in NAMECs reduced PKC activity (Figure S3C). Together, these results confirmed
that PKCα activity operated downstream of PDGFR and depended on the actions of PLCγ.
Since PDGF autocrine signaling was activated in cells that had undergone an EMT, we
reasoned that this might be important for their survival and that the inhibition of PDGFR
could be useful for the selective killing of CSCs. Co-mixed NAMEC-Tom-RAS and HMLE-
GFP-RAS cells were treated with each of these inhibitors and NAMEC-Tom-RAS cells
exhibited a 3.2–3.8 fold lower LC50 for the PDGFR inhibitors tested relative to HMLE-
GFP-RAS cells (Figure 4G). It thus appeared that the EMT, along with the acquisition of
CSC-like traits, was accompanied by a downregulation of EGFR and concomitant
upregulation of PDGFR, highlighting the preferential utilization of different signaling
networks in different cellular states. We noted that a pharmacologic inhibitor that is
completely specific to inhibition of PDGFRα/β is currently unavailable and the two
PDGFRα/β inhibitors used here cross-inhibited c-KIT- and VEGFR-associated tyrosine
kinases.
Cell-state dependent utilization of c-FOS or FRA1 during EMT
We sought to elucidate the mechanism(s) through which PKCα acts to support the
mesenchymal cell state and to identify downstream mediators of PKCα in cells that have
undergone an EMT. We surveyed for PKCα substrates identified by others in various
cellular contexts (Abate et al., 1991; Gruda et al., 1994; Kang et al., 2012) and focused on
those upregulated together with PKCα expression during an EMT (Figure S4A). Among
genes examined, FOSL1 mRNA (encoding the FRA1 protein) was the most upregulated
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target of PKCα in the HMLE-Twist, HMLE-Snail and HMLE-Slug cells. This prompted us
to further examine the connection between PKCα and FRA1. Of note, we could not exclude
the possible functional importance of other genes encoding PKCα substrates that were not
transcriptionally upregulated.
FRA1 is a member of the FOS family of transcription factors that when phosphorylated
downstream of PKCα signaling associate with members of the JUN family of transcription
factors to form heterodimeric activator protein-1 (AP-1) complexes to transcriptionally
regulate target gene expression (Abate et al., 1991). To confirm that FRA1 operated
downstream of PKCα, NAMECs were treated with either of two PKCα inhibitors. Levels of
p-FRA1S265 were strongly downregulated whereas total FRA1 levels remained unchanged,
indicating that FRA1 phosphorylation was indeed dependent on PKCα activity (Figure 5A).
We speculated that c-JUN (encoded by JUN) was a binding partner of FRA1 as our previous
work demonstrated induction of c-JUN during passage through an EMT (Scheel et al.,
2011). Indeed, we found that total and phospho-c-JUNS63 as well as the Jun N-terminal
kinase (JNK), which is required for the activation of c-JUN, were upregulated in
mesenchymal cell populations (Figures 5B and S4B). Other JUN family members, JUNB
and JUND, did not exhibit consistent up- or down-regulation following passage through
EMT, indicating that their expression was not cell-state dependent. Unexpectedly, c-FOS
(encoded by FOS), which has been extensively documented as a partner of c-JUN (Eferl and
Wagner, 2003), was downregulated during passage through an EMT (Figures 5B and S4B).
Total and phospho-FRA1S265 levels, by contrast, were increased. Hence, epithelial and
mesenchymal cells appeared capable of assembling AP-1 complexes, but of quite different
composition, in that FRA1 seemed to replace c-FOS as the partner of JUN following
passage through an EMT.
We sought to understand the functional significance of the c-FOS-FRA1 molecular switch
during the EMT. Knockdown of FRA1 with two independent shRNAs preferentially
reduced NAMEC-Tom cell numbers but had a lesser impact on HMLE-GFP cells (Figures
5C and S4C). In contrast, HMLE-GFP cells were preferentially depleted upon c-FOS
knockdown while NAMEC-Tom cells were significantly less affected. This highlighted the
cell-state specific dependence on either c-FOS or FRA1 for maintaining cell viability
(Figure 5C). We performed co-immunoprecipitation experiments to validate the formation
of AP-1 complexes and the nature of their constituent subunits. In NAMECs,
immunoprecipitation of FRA1 showed physical association with c-JUN, JUNB and JUND
(Figure 5D). In a reciprocal manner, pull-down of c-JUN demonstrated its interaction with
FRA1 but not c-FOS (Figure 5D). The converse pattern was observed in HMLE cells, in
which c-FOS strongly associated with JUNB and JUND but not c-JUN, which was
downregulated in the epithelial state (Figure 5D). Furthermore, chromatin
immunoprecipitation analyses revealed c-FOS binding to the promoters of genes encoding
E-cadherin and Crumb3, two key epithelial proteins, in HMLE cells. The same promoters,
however, were not bound by FRA1 in NAMECs, which did not express either protein
(Figure 5E). Hence, during execution of the EMT program, there is a switch from the use of
c-FOS to FRA1 as the preferred component of AP-1 transcription factor complexes.
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Control of FRA1 activation by ERK signaling
We sought to uncover additional downstream targets of PKCα beyond FRA1 that might be
crucial for supporting the EMT program. c-Raf is another substrate of PKCα that sustains
activation of ERK signaling and helps to promote mesenchymal cell phenotypes (Kolch et
al., 1993). Examination of proteins involved in the ERK pathway revealed increased
expression of both total and phosphorylated levels of B-RAF, c-RAF and ERK1/2 in the
mesenchymal cell populations (Figure 5F).
As ERK signaling is commonly controlled by RAS activity, we tested whether mesenchymal
cells contained higher RAS expression or activated RAS than did epithelial cells.
Interestingly, levels of total RAS and activated GTP-bound RAS were similar among
epithelial and mesenchymal cell types (Figures 5F and 5G). This led us to propose that the
enhanced ERK signaling in the mesenchymal cell state was primarily mediated by PKCα
signaling, rather than through the RAS-RAF pathway. To test this notion, we exposed
NAMECs to PKCα inhibitors and found reduced p-c-RAF, p-MEK1/2 and p-ERK1/2 levels
(Figures 5H and S4D). Inhibitors of PDGFR signaling, likewise, blunted ERK signaling as
indicated by decreased p-c-RAF, p-MEK1/2 and p-ERK1/2 levels (Figure S4E). Hence,
enhanced activity of ERK signaling during EMT was conferred in part by signaling through
PDGFR and PKCα.
FRA1, which we showed earlier to be downstream of PKCα, has also been reported to serve
as a direct substrate of p-ERK1/2 (Kakumoto et al., 2006). Thus we speculated that the
increased p-FRA1 activity in the mesenchymal cells could be further augmented by elevated
ERK signaling. Accordingly, blockade of ERK1/2 phosphorylation with a MEK inhibitor in
NAMECs decreased p-FRA1 levels but did not affect the levels of total FRA1 or p-c-JUN
(Figure 5I), confirming that ERK1/2 signaling promoted the phosphorylation of FRA1.
Together, these observations indicate that PKCα signaling in mesenchymal cells leads to
activation of FRA1, downstream of both PKCα and ERK1/2.
Role of FRA1 in tumor initiation by breast cancer cells
We sought to understand whether FRA1 might be functionally important for the subset of
human breast cancer cells that exhibit mesenchymal traits. Accordingly, we depleted FRA1
by RNAi in two basal-like (basal B) breast cancer cell lines, MDA-MB-231 and SUM159,
both of which do not express HER2, estrogen receptor (ER), or progesterone receptor (PR).
In both cell lines, FRA1 depletion resulted in a morphologic response resembling a
mesenchymal-epithelial transition (MET), in which otherwise mesenchymal-like cancer
cells formed cobblestone sheets resembling those assembled by epithelial cells (Figure 6A).
The loss of VIM, FN1 and CDH2 mRNA expression accompanied by the gain of CDH1
mRNA expression was observed (Figure 6B). Moreover, in both cell lines depleted of
FRA1, FOS mRNA expression, which we had previously associated with the epithelial cell
phenotype, was strikingly increased (Figure 6C).
FRA1 knockdown did not significantly affect proliferation of MDA-MB-231 or SUM159
cells in vitro (Figure S5A). However, FRA1-depleted cells formed tumors with a reduced
frequency and were substantially smaller size relative to shRNA controls when xenografted
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into female NOD-SCID mice (Figure 6D). In contrast, depletion of FRA1 in two luminal-
like, hormone receptor-positive (ER+/PR+) breast cancer cell lines, MCF7-Ras and T47D,
did not affect their proliferation, expression of EMT-associated markers, tumor formation,
or tumor growth (Figures S5A–S5C). These observations suggested that FRA1 was
important for the tumorigenic potential of breast cancer cells forming basal-like or triple-
negative tumors but not those forming luminal tumors.
This led us to speculate that FRA1 expression might be restricted to the more mesenchymal,
CSC-enriched compartments within basal-like human breast tumors. Previous studies have
shown that purified CD44+ or protein C receptor-positive (PROCR+) cells tend to be
enriched for CSCs in primary human tumors, whereas the CD24+ fraction was depleted of
these cells (Al-Hajj et al., 2003; Shipitsin et al., 2007). Both CD44+- and PROCR+-purified
cells also demonstrated elevated mRNA expression of VIM (403x), FN1 (48x) and TWIST
(6.6x) (Shipitsin et al., 2007). Thus, we further analyzed the expression of FOSL1 and FOS
in these CD44+/PROCR+ or CD24+ cells isolated from human tumors (Shipitsin et al.,
2007). Across multiple specimens, FOSL1 was upregulated in the CD44+/PROCR+ fraction,
while FOS was elevated in the CD24+ fraction (Figure S5D) providing additional support
that FOSL1 expression is associated with CSC-enriched CD44+ populations bearing
mesenchymal properties.
Effects of the Twist and Snail EMT-TFs on FRA1 expression
The increased expression of FRA1 in the EMT TF-induced mesenchymal cells and
NAMECs correlated closely with the abundance of several EMT-TFs, suggesting that the
latter might directly induce FOSL1 mRNA expression. To test this notion, we fused ER to
either Twist or Snail (HMLE-Twist-ER and HMLE-Snail-ER) (Mani et al., 2008) and
demonstrated that activation of Twist or Snail upon tamoxifen exposure led to increased
levels of FOSL1 mRNA in a time-dependent manner (Figure 6E). We next assessed whether
Twist or Snail bound at the FOSL1 promoter using chromatin immunoprecipitation (ChIP)
and could detect their binding at the transcription start site and within the first intron of
FOSL1 (Figure 6F). These regions contained E-box motifs (CANNTG), which Twist and
Snail are known to bind. In contrast, the promoter of FOS was only weakly enriched for
Twist and Snail binding (Figure 6F). Together, these data suggested that FOSL1 was a direct
target of Twist and of Snail.
To determine whether the ability of FRA1 to drive gene transcription was dependent on the
expression of EMT-TFs, we utilized a luciferase reporter containing the sequence of a
previously reported FRA1-bound gene promoter (FRA1-wild-type-binding site: FRA1-WT-
BS) as well as a mutant FRA1-binding construct (FRA1-mut-BS) (Stinson et al., 2011). In
NAMECs, knockdown of FRA1 abrogated luciferase activity of the FRA1-WT-BS but not
FRA1-mut-BS (Figure 6G, left panel). Similarly, knockdown of TWIST or SNAIL
diminished FRA1-dependent expression of the FRA1-WT-BS reporter (Figure 6G, left
panel). FOSL1 mRNA expression was also reduced upon either TWIST or SNAIL
knockdown (Figure 6H).
In a reverse experiment, we overexpressed FRA1 in the NAMEC11 cell line, which had
undergone a partial EMT. Overexpression of FRA1 induced FRA1-WT-BS but not FRA1-
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mut-BS luciferase activity (Figure 6G, right panel). Likewise, Twist and Snail
overexpression in these cells was able to induce transcription of the FRA1-WT-BS reporter
(Figure 6G, right panel). The wild-type AP-1 reporter containing tandem repeats of AP-1
response element was used as a positive control (Figure 6G). Therefore, these various lines
of evidence confirmed that FOSL1 levels were transcriptionally regulated by two master
EMT-TFs and in a direct manner.
To demonstrate that FRA1 plays a functionally significant role downstream of EMT-TFs,
we activated Twist or Snail in HMLE-Twist-ER or HMLE-Snail-ER cells in the presence or
absence of two different FRA1 shRNAs, and assessed the ability of these cells to transit into
the mesenchymal state. HMLE-Twist-ER and HMLE-Snail-ER cells that expressed control
shRNA underwent an EMT within one week after 4-OH-tamoxifen exposure (Figures 7A
and 7B). However, FRA1-depleted cells were blocked in their ability to undergo an EMT
upon Twist or Snail activation, and retained their epithelial phenotype (Figures 7A and 7B).
These observations reinforced our conclusion that FRA1 acts as an effector of the EMT
program that is required for its execution.
Relevance of FRA1 and PKCα expression to clinical breast cancer
The functional significance of FRA1 in mediating cell-state transition and in maintaining
CSCs led us to wonder whether its expression might also be relevant to clinical breast
cancer. We speculated that FOSL1 expression was restricted to basal B and triple-negative
breast cancer (TNBC) tumors and cell lines, as these bear strong molecular hallmarks of
cells that have activated an EMT program (Shipitsin et al., 2007). These subtypes are also
thought to contain a high representation of CSCs, thereby favoring relapse, metastasis and
poor overall survival. Indeed, FOSL1 mRNA levels, but not those of other AP-1 subunits,
were elevated in the basal B subtype of breast cancer cell lines surveyed, whereas its levels
were reduced in the basal A cell lines and were essentially undetectable in all luminal
subtype cell lines (Neve et al., 2006) (Figure S6A).
From a compendium of clinical datasets, we observed high FOSL1 expression significantly
correlated with poor distant metastasis-free survival (DMFS), while high FOS or FOSB
expression associated with better survival (Figures 7C and S6B). The expression levels of
other AP-1 subunits did not predict patient outcome (Figure S6B). Additionally, higher
PKCα and FOSL1 mRNA expression was significantly associated with HER2−, ER− or PR−
status, as well as with triple-negative tumors (Figure 7D). Their expression was also
elevated in tumors bearing BRCA1 mutations and in breast cancer cell lines containing p53
mutations (Figure 7D). Moreover, FOSL1, PDGFRA and PDGFRB mRNAs were more
highly expressed in the claudin-low subtype of breast cancer that is thought to express the
most mesenchymal properties (Figure S6C).
To exclude the possibility that FOSL1 mRNA expression was derived from infiltrating
stromal cells, we examined its protein expression in breast tumor microarrays derived from
patients whose tumors had been scored for tumor grade. Moderate-to-strong nuclear FRA1
staining was present predominantly in the neoplastic cells of Grade 3 tumors that were
typically hormone receptors-negative but far less commonly in Grade 1 and Grade 2 tumors,
or in the normal mammary epithelium (Figure 7E). A similar trend could be observed with
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cytoplasmic and membrane-localized PKCα in which moderate-strong staining was most
common in Grade 3 tumors relative to Grade 1 and 2 tumors (Figure 7E). Taken together,
these results reinforced the notion that FRA1, along with PKCα, function as important
mediators of the behavior of aggressive basal-like and TNBCs.
In light of the findings that PKCα inhibitors, administered systemically, could inhibit the
growth of breast cancer cells bearing mesenchymal traits and the observation that triple-
negative breast tumors tend to express elevated levels of PKCα, we tested whether PKCα
inhibition could be useful therapeutically against patient-derived tumor samples. We
generated three patient-derived breast cancer xenografts from triple-negative tumors
(EL12-58, EL12-15 and EL11-26) that had been serially passaged in NOD-SCID mice
following their removal from patients. We then transplanted these tumor fragments
orthotopically into a fresh set of female NOD-SCID mice and on the same day, subjected
them to either a PKCα inhibitor or vehicle control that was administered intraperitoneally
daily for six weeks. With all three xenograft lines, tumors that formed in the PKCα
inhibitor-treated mice were consistently smaller (EL12-15: 65.7%, EL11-26: 53.3%,
EL12-58: 39.5%) than the control group (Figure 7F). Thus, inhibition of PKCα appeared to
be a potentially useful strategy for targeting triple-negative breast tumors.
DISCUSSION
We and others have argued previously that effective treatment of carcinomas depends upon
the elimination of minority CSCs in addition to the majority non-CSC cells in these tumors
(Creighton et al., 2009; Dalerba et al., 2007; Gupta et al., 2009). This led us to exploit the
observation that the EMT program generates cells that are enriched for stem cell and CSC
properties in order to identify signaling networks that are preferentially utilized in the
cellular products of an EMT (Figure 8). Our present findings demonstrate that PKCα is a
central regulatory node activated by PDGFR in CSC-enriched populations. While PKCα has
been implicated in promoting cancer progression (Griner and Kazanietz, 2007; Lonne et al.,
2010), its connection to cell-state transitions and CSCs has been unclear. As a proof-of-
principle, we showed the pharmacologic inhibition of PKCα can target breast CSCs
selectively and that clinically effective compounds inhibiting PKCα may prove
therapeutically useful for treating certain breast tumors.
The selective dependence of the epithelial versus mesenchymal MECs on the function of
EGFR and PDGFR is clinically relevant, because EGFR inhibitors are being tested in
clinical trials or in clinical use but often resulting in limited clinical responses (Carey et al.,
2010). Several studies have pointed out that such inhibitors enrich for CSCs and can lead to
the outgrowth of more aggressive, chemotherapy-resistant tumor cell populations (Buck et
al., 2007; Thomson et al., 2005). These studies suggest that the presence of epithelial- and
mesenchymal-like carcinoma cells within tumors requires the elimination of both cell types.
The EMT program is initially required for invasion and dissemination of tumor cells
whereas MET has been demonstrated to promote colonization and metastatic outgrowth
(Ocana et al., 2012; Tsai et al., 2012). An increasing number of observations suggest that
both tumor-initiation and metastatic outgrowth depend on coexisting subpopulations of
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epithelial and mesenchymal subpopulations; conversely tumors containing exclusively one
or the other subpopulation appear to be poorly suited in enabling both of these processes
(Brabletz, 2012; Celia-Terrassa et al., 2012; Ocana et al., 2012). This implies that while the
inhibition of cancer cells bearing a mesenchymal phenotype could be useful for preventing
tumor-initiation and/or dissemination, such a therapeutic strategy needs to be complemented
with treatments that target already-established metastases and their complements of non-
CSC epithelial cells. Moreover, the EMT should be viewed as generating a spectrum of
phenotypic states depending on the extent to which this program is completed by epithelial
cells, and partial completion of this program may be essential for the formation of CSCs and
thus the founding of metastases. Future work will require more detailed measurements of the
extent to which the various intermediate states depend on the epithelial versus mesenchymal
signaling circuits described here.
Our initial efforts to distinguish molecular features between mammary CSCs and non-CSCs
have led to the identification of kinase inhibitors that may be useful in preclinical models of
human breast cancer. We speculate that the EMT program may also be adopted by other
carcinoma cell types to drive tumor progression and metastasis. If so, the approach used to
identify therapeutic compounds and pathways unique to mammary carcinoma CSCs
described here may be extended to target CSCs present in the tumors arising from other
epithelial tissues.
EXPERIMENTAL PROCEDURES
Kinase inhibitor screen
Kinase inhibitors and other biochemicals were obtained from sources listed in the
Supplemental Information. To set up the screen, 75,000 NAMEC-Tom and 15,000 HMLE-
GFP cells were seeded into each well of a 6-well tissue culture plate. The following day,
fresh media containing inhibitors were added. For control treatment, DMSO was added.
Fresh media containing inhibitors were replaced daily during the six day period. For
analysis, cells were trypsinized and flow cytometry was performed to analyze the proportion
of surviving cells relative to DMSO-treated control for NAMEC-Tom or HMLE-GFP cells.
To test the effects of these inhibitors on CSCs and non-CSCs, NAMEC-RAS-Tom and
HMLE-RAS-GFP were used in similar co-mixed experiments.
Cell Lines and Cell Culture
HMLE cells and NAMECs were maintained in MEGM (Lonza). Other commonly used
breast cancer cell lines are listed in Supplemental Information. HMLE were generated from
HMECs immortalized using retroviral vectors to express the catalytic subunit of the human
telomerase enzyme, hTERT and the SV-40 Large T antigen. NAMECs were isolated based
on the observation that mesenchymal cells were less adherent than epithelial cells to tissue
culture surfaces. HMLE cells were grown to 50% confluency, followed by differential
trypsinization for one minute with 0.05% trypsin. Detached cells were collected and re-
plated at approximately 200 cells per well of a 24-well plate. Upon expansion, wells were
screened for populations with a mesenchymal phenotype that could be stably propagated.
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Gene expression microarray and analyses
Total RNA was extracted and expression profiling of coding genes was carried out using
Illumina HumanRef-8 v2 BeadArrays. Gene expression data from Illumina array is
normalized by quantile normalization. Differential genes are called using LIMMA with
p<0.05 and fold change > 1.2.
Patient-derived breast cancer xenograft establishment and therapy
Primary human breast cancer samples were obtained from the Dana-Farber Cancer Institute
with patients’ consent and institutional review board approval. These samples were
subsequently de-identified to protect patient confidentiality. Patient-derived breast tumor
fragments (approximately 3×1×1 mm) were inserted bilaterally into the inguinal mammary
fat pads of 6–8 week-old NOD-SCID-IL2Rγc−/− female mice for initial establishment of
tumors within 2 hr of surgery, and subsequently expanded in NOD-SCID mice once
established. Established TNBC tumors (EL12-15, EL12-58 and EL11-26) were implanted
into cohorts of 6–8 week-old female NOD-SCID mice. Treatment was initiated at the time
of tumor implantation and the mice were randomized into two groups: vehicle (10% DMSO
in saline) and treatment (Ro-31-8220, 5 mg/kg/day intraperitoneally). Tumors were
collected and weighed after six, eight or 11 weeks. All research involving animals complied
with protocols approved by the MIT Committee on Animal Care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
Conventional cancer therapeutics tend to preferentially eliminate the non-CSCs within a
tumor, leaving behind residues of more resistant CSCs that can subsequently generate
clinical relapses, indicating the need to specifically target the CSCs within tumors. The
identification of key regulatory mechanisms that distinguish CSCs from non-CSCs is
therefore critical for CSC-targeted therapy. We find that the PKCα signaling network is
activated specifically in CSCs, rendering them preferentially susceptible to specific
pharmacologic agents. In addition, we uncovered FRA1 to be a key transcription factor
downstream of PKCα that drives CSC function. The inhibition of either PKCα or FRA1
can abolish tumor initiation, highlighting the potential therapeutic value of targeting these
proteins in epithelial cancers such as breast cancer.
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HIGHLIGHTS
• Inhibition of PKCα preferentially targets breast cancer stem cells
• Activation of an EMT program induces a shift from EGFR to PDGFR signaling
• Activation of an AP-1 molecular switch involving c-FOS and FRA1 in CSCs
• FRA1 is required for the EMT phenotype and tumor-initiation ability
Tam et al. Page 18
Cancer Cell. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Global gene expression analyses reveal differentially regulated kinases whose mRNA expression are altered following EMT
(A) Representative phase contrast images of the indicated cell lines (left) and quantitative PCR for gene expression of EMT
markers in these cell lines relative to HMLE-vector cells (right). Numbers denote fold change. Scale bar: 40 μm.
(B) Mammosphere-forming ability of HMLE cells transduced with Twist, Snail or Slug.
(C) Heat map of the top differentially regulated genes between HMLE-Twist, HMLE-Snail, HMLE-Slug and control cells (fold
change > 1.2).
(D) Phase contrast images of NAMEC and HMLE cells. Scale bar: 40 μm.
(E) Quantitative PCR for gene expression of EMT markers in NAMEC8 and HMLE cells.
(F) Western blots of EMT-associated proteins in NAMECs and HMLE cells. Samples were loaded and analyzed on the same
blot.
(G) Flow cytometry analysis for the expression of CD44 and CD24 surface antigens on NAMECs and HMLE cells.
(H) Mammosphere-forming ability of NAMECs and HMLE cells.
*p<0.05. Data presented as mean ± s.e.m. See also Table S1 and Figure S1.
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Figure 2. PKCα inhibition selectively targets cells that have undergone an EMT and are enriched for stem cell properties
(A) Approach for testing kinase inhibitors to identify stem cell-specific compounds. NAMEC-Tom and HMLE-GFP cells were
co-mixed and seeded for 24 hr prior to daily inhibitor treatment. Viable cells were analyzed after six days by flow cytometry to
determine the proportion of NAMEC-Tom or HMLE-GFP cells.
(B) The proportion of surviving NAMEC-Tom and HMLE-GFP cells as visualized by fluorescence microscopy after six days of
inhibitor treatment.
(C) Viable cell populations were analyzed by flow cytometry that segregated and counted NAMEC-Tom and HMLE-GFP cells
after treatment with PKCα inhibitors. Cell numbers of each population were normalized to corresponding NAMEC-Tom or
HMLE-GFP cells of DMSO-treated controls.
(D) Dose-response curves of NAMEC-Tom and HMLE-GFP cells treated with PKCα inhibitors, paclitaxel or staurosporine.
The difference in LC50 between NAMEC-Tom and HMLE-GFP cells at each inhibitor is indicated. Curves for each cell type
were generated using non-linear regression curve fit with the variable slope model.
(E) Quantitative PCR for PKCα mRNA level in CD44hi/CD24lo, CD44lo/CD24hi and unfractionated cell compartments of
HMLE cells.
(F) Levels of total PKC kinase activity in EMT-TF-induced HMLE and NAMEC cells relative to HMLE control cells.
(G) Measurement of apoptosis by Annexin V-APC in mixed NAMEC-Tom and HMLE-GFP cells treated with Ro-31-8220 for
three days.
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(H) Quantitative PCR for validation of PKCα RNAi knockdown in NAMEC-Tom and HMLE-GFP cells three days after
puromycin selection. * denotes significantly different from Luc sh control.
(I) Effects of PKCα RNAi on the growth kinetics of NAMEC-Tom and HMLE-GFP cells as measured by WST assay. * denotes
significantly different from Luc sh control.
*p<0.05. Data presented as mean ± s.e.m. See also Figure S2.
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Figure 3. Cell state-specific kinase expression is conserved upon oncogenic RASG12V transformation and in CSCs
(A) Assessment of the tumorigenicity of NAMEC-RAS or HMLE-RAS cells injected subcutaneously into NOD-SCID mice at
limiting dilutions of cells, as determined by tumor mass. Numbers indicate the frequency of tumor formation. Western blot
indicates levels of RAS expression.
(B) Quantitative PCR for gene expression of selected kinases in HMLE-Twist-RAS, HMLE-Snail-RAS, HMLE-Slug-RAS and
NAMEC-RAS cells relative to HMLE-RAS cells.
(C) Dose-response curves of NAMEC-Tom-RAS and HMLE-GFP-RAS cells treated with PKCα inhibitors, paclitaxel or
staurosporine. Differential sensitivity to treatment at LC50 is indicated.
(D) Immuno-histochemistry detection of total PKCα and p-PKCαT497 in sections of equivalent size (~0.3 g) NAMEC-RAS and
HMLE-RAS tumors. NAMEC-RAS tumors were 15 weeks after inoculation of 2.5 × 104 cells and HMLE-RAS tumors were 11
weeks after inoculation of 5 × 105 cells.
(E) Assessment of the tumorigenicity of subcutaneously xenografted NAMEC-RAS cells (5 × 104) in mice treated with daily
intraperitoneal administration of the indicated agents, as determined by tumor mass. Treatments began on the same day as the
cells were implanted. Tumors were collected 15 weeks post-implantation.
(F) Assessment of the tumorigenicity of established NAMEC-RAS tumors following treatment with the indicated agents.
NAMEC-RAS cells (5 × 104) were subcutaneously xenografted in mice and allowed to reach approximately 2 mm in diameter
after four weeks. Subsequently, mice were treated with daily intraperitoneal administration of the indicated agents for 30 days.
Tumors were collected six weeks later and tumor masses were determined.
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*p<0.005. Data presented as mean ± s.e.m.
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Figure 4. EMT induces a switch from EGFR to PDGFR signaling
(A) Western blots of total and p-EGFRY1068 in the indicated EMT-TF-induced HMLE and NAMEC cells. Samples were loaded
and analyzed on the same blot.
(B) Dose response curves (left) of the sensitivities of HMLE-RAS-GFP and NAMEC-RAS-Tom cells to EGFR inhibitors. The
difference in fold sensitivity between both cell types at LC50 is indicated. Representative immunofluorescent images are shown
at the right.
(C) Quantitative PCR for PDGFRA, PDGFRB, PDGFC and PKCα mRNA expression in breast cancer cell lines. Numbers
indicate fold change.
(D) Quantitative PCR for PDGFC expression in mesenchymal and epithelial cells. * denotes significantly different from HMLE
or HMLE-vector, p<0.05.
(E) Western blots of PDGFRα, PDGFRβ, PLCγ1 and PLCγ2, along with protein phosphorylation, in NAMECs and EMT-TF-
induced cells. Sample loading controls (GAPDH) were the same as Figure 4A. Samples were loaded and analyzed on the same
blot.
(F) Western blot analysis of NAMECs cultured in the absence of growth supplements (bovine pituitary extract, EGF,
hydrocortisone and insulin) and treated with either a PDGFC neutralizing antibody (20 μg/ml) or a PDGFR inhibitor (1 μM)
(top), or upon exposure to PDGFC (100 ng/ml) (bottom). PDGFR activity is represented by the phosphorylation of
PDGFRβY751.
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(G) Dose response curves (left) of HMLE-RAS-GFP and NAMEC-RAS-Tom cells to PDGFR inhibitors. The difference in fold
sensitivity between both cell types at LC50 is indicated. Representative immunofluorescent images are shown at the right.
Data presented as mean ± s.e.m. See also Figure S3.
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Figure 5. PDGFR signaling results in PKCα and ERK1/2 activation that induces FRA1
(A) Western blot analysis of the effects of inhibiting PKCα (using Ro-31-8220 or bisindolylmalmide I) or PDGFRα/β (using
PDGFR Inh III or PDGFR Inh IV) for 30 minutes on the phosphorylation status of FRA1 and c-JUN in NAMECs.
(B) Western blots of AP-1 family member subunits in epithelial and mesenchymal cell lines. Samples were loaded and analyzed
on the same blot.
(C) Relative cell number analyses of the effects of FRA1 or c-FOS knockdown on the viability of NAMEC-Tom and HMLE-
GFP cells. * denotes significantly different from vector control, p<0.05. Data presented as mean ± s.e.m.
(D) Western blots for proteins immunoprecipitated with FRA1 or c-JUN antibodies in NAMECs, and with c-FOS antibody in
HMLE cells. Whole cell lysates were used as positive controls while pull-down with IgG or without an antibody was performed
as negative controls.
(E) Occupancy of c-FOS and FRA1 on the promoters of CDH1 and CRB3 (encoding Crumb3). A normalization probe for non-
enriched region is located within intron 1 (CDH1) or intron 3 (CRB3). Control ChIP was performed with an IgG antibody.
(F) Western blots of total and phosphorylated B-RAF, c-RAF and ERK1/2 in TF-induced EMT and NAMEC cells. Sample
loading controls (GAPDH) were the same as Figure 5B. Samples were loaded and analyzed on the same blot.
(G) The amount of GTP-bound Ras was compared between epithelial and mesenchymal cell states by immunoprecipitation with
Raf-Ras Binding Domain (RBD) beads followed by blotting with a pan-Ras antibody. As a negative control, lysates were treated
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with GDP which blocked the ability of Ras to bind Raf-RBD beads. β-actin from whole cell lysate (prior to IP) was used as a
loading control.
(H) Western blots of phosphorylated proteins of B-RAF, c-RAF, MEK1/2 and ERK1/2 in NAMEC cells following treatment
with PKCα inhibitors for 30 minutes.
(I) Western blots of p-FRA1 levels in NAMEC cells following MEK inhibition for 30 minutes.
See also Figure S4.
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Figure 6. FRA1 is a transcriptional target of Twist and Snail that is indispensible for tumorigenicity of basal-like breast cancer cells
(A) Phase contrast images showing the morphology of MDA-MB-231 or SUM159 cells after FRA1 knockdown for 10 days.
Scale bar: 40 μm.
(B) Quantitative PCR for gene expression of mesenchymal markers in FRA1-depleted cells. * denotes significantly different
from Luc sh.
(C) Quantitative PCR for gene expression of FOS and FOSL1 after FRA1 knockdown in MDA-MB-231 and SUM159 cells.
(D) Assessment of the tumorgenicity of cancer cells following FRA1 knockdown. 1 × 106 MDA-MB-231 or SUM159 cells were
implanted subcutaneously into female NOD-SCID mice, tumors were extracted after 4 weeks, and tumor masses were
determined. Numbers indicate the frequency of tumor formation. * denotes significantly different from Luc sh-derived tumors.
(E) Changes in gene expression of EMT markers in Twist-ER and Snail-ER cells after the addition of 4-OHT. Cells were
exposed to 4-OHT for the duration examined.
(F) Occupancy of Twist and Snail on the FOSL1 or FOS promoter. Binding enrichment was normalized to input DNA and
plotted relative to probe 12 (FOSL1) or probe 9 (FOS).
(G) Effect of Twist and Snail on FRA1-reporter luciferase activity. Firefly luciferase was normalized against SV40-Renilla-
luciferase transfection control and the values were compared to control Scr sh or vector overexpression. * denotes significantly
different from Scr sh or vector control; n=6.
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(H) Quantitative PCR for FOSL1 expression after Twist or Snail knockdown in NAMECs. * denotes significantly different from
vector control.
*p<0.05. Data presented as mean ± s.e.m. See also Figure S5.
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Figure 7. FRA1 is a gatekeeper of the EMT program and is clinically correlated with basal-like or triple-negative breast tumors
(A) Phase contrast images showing morphology of Twist- or Snail-induced EMT cells after FRA1 depletion. Scale bar: 40 μm.
(B) Quantitative PCR for gene expression of EMT-associated mRNAs in Twist-ER and Snail-ER cells following FRA1
knockdown after seven days of 4-OHT exposure.
(C) Kaplan-Meier plots of distant metastasis-free survival of breast cancer patients. Patient groups separated based on FOSL1
(top), FOS (middle) or JUN (bottom) mRNA expression.
(D) Microarray meta-analyses of PKCα and FOSL1 mRNA expression in human primary breast cancer tumor subtypes
(Waddell et al., 2010), and in breast cancer cell lines bearing p53 mutation (Neve et al., 2006).
(E) Immunohistochemistry analyses of human breast cancer samples for PKCα and FRA1 protein expression in breast tumors
with different grades. Representative staining results are shown at the left. The numbers of graded tumors or normal tissues that
were classified based on FRA1 or PKCα expression are depicted at the right. * denotes significantly different from Grade 1,
Grade 2 or normal specimens.
(F) Effects of PKCα inhibitor administration (5 mg/kg/day) on the growth of patient-derived breast tumor xenografts in NOD-
SCID mice. Treatment was initiated immediately following implantation and continued for five weeks, tumor masses were then
determined. * denotes significantly different from vehicle.
*p<0.05. Data presented as mean ± s.e.m. See also Figure S6.
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Figure 8.
Scheme depicting the differential utilization of signaling networks between non-CSCs and CSCs upon the activation of an EMT
program.
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